Prostat Karsinomlarında E-kadherin ve Beta-katenin Ekspresyonunun Gleason Skoru ve Diğer Prognostik Faktörler ile Karşılaştırılması

Abstract

Objectives: Cell adhesion complex E-cadherin and beta-catenin have important roles in tissue integrity, organization, protection of epithelial phenotype, transcription and proliferation of epithelial cells. Changes in these molecules have been reported in some epithelial malignancies. In this study, with the evaluation of the role of E-cadherin and beta-catenin immunohistochemical expression status in prostate carcinomas with Gleason score and other prognostic factors and the role of these molecules in the pathogenesis of prostate carcinoma were investigated. Materials and Methods: One hundred fifty-six radical prostatectomy cases diagnosed as prostate adenocarcinoma between 2003 and 2008 years at the Gazi University, Faculty of Medicine, Department of Pathology, were included in the study. The prognostic factors of the cases were retrospectively reviewed and recorded. The cases were divided into groups according to the Gleason score. E-cadherin and beta-catenin antibodies and tumor cells were evaluated semi-quantitatively according to the percentages and severity of immunohistochemical expression. The relationship between E-cadherin and beta-catenin expression levels and Gleason score and other prognostic factors were statistically investigated. Results: With E-cadherin, 47 (30%) of 156 cases showed loss of expression. There was a statistically significant difference between loss of e-cadherin expression and high Gleason score and seminal vesicle invasion. Expression loss was detected in 79 (50%) of 156 cases with beta-catenin. A statistically significant relationship was found between loss of beta-catenin expression and high Gleason score, seminal vesicle invasion and extraprostate spread. Conclusion: In our study, a statistically significant difference was found between E-cadherin and beta-catenin expression loss and high Gleason score, seminal vesicle invasion and extra-prostate spread. The findings supported the role of these molecules in the pathogenesis of prostate carcinoma. However, due to the absence of metastatic tumors and their relationship with clinical stage and clinical follow-up, no comment could be interpreted for the role of these molecules in aggressive tumors.

Keywords

• Prostate Cancer
• Prostate
• E-cadherin
• Beta-catenin
• Gleason Score

Ethical Statement

Etik Kurul Onayı: Gazi Üniversitesi Tıp Fakültesi Etik Kurulu’ndan 27.11.2006 tarih ve 363 sayı numarası ile alınmıştır. Hasta Onayı: Bilgilendirilmiş onam alınmıştır. Hakem Değerlendirmesi: Editörler kurulunun dışından olan kişiler tarafından değerlendirilmiştir. Yazarlık Katkıları Konsept: T.B., Dizayn: T.B., Veri Toplama veya İşleme: T.B., Analiz veya Yorumlama: T.B., Ö.E., Literatür Arama: T.B., Yazan: T.B. Çıkar Çatışması: Yazarlar tarafından çıkar çatışması bildirilmemiştir. Finansal Destek: Bu çalışma Gazi Üniversitesi Bilimsel Araştırma Projeleri Birimi tarafından 01/2007-15 proje numarası ile desteklenmiştir.

References

1. 1. Moch H, Humphrey PA, Ulbright TM, Reuter VE eds. WHO Classification of Tumors of the Urinary System and Male Genital Organs. 4st ed.Lyon: International Agency for Research on Cancer (IARC); 2016. p. 138-154.
2. 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
3. 3. Onder TT, Gupta PB, Mani SA, et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68:3645–3654.
4. 4. Giroldi LA, Shimazui T, Schalken JA, et al. Classical cadherins in urological cancers. Morphologie. 2000;84:31–38.
5. 5. Su Y, Simmen RC. Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis. 2009;30:331–339.
6. 6. Chen HN, Yuan K, Xie N, et al. PDLIM1 Stabilizes the E-Cadherin/betaCatenin Complex to Prevent Epithelial-Mesenchymal Transition and Metastatic Potential of Colorectal Cancer Cells. Cancer Res. 2015;76:1122–1134.
7. 7. Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9:418–428.
8. 8. Krishnamurthy N, Kurzrock R. Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors. Cancer Treat Rev. 2018 ;62:50–60.

9. 9. Kallakury BVS, Oliver J, Shhehan CE, et al. Co-downregulation of cell adhesion proteins alfa and beta catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol. 2001;32:849–855.
10. 10. Wang J, Krill D, Torbenson M, et al. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostattectomy specimens. Urol Res. 2000;28:308-315.
11. 11. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of Ecadherin and beta catenin in human prostate cancer. Urol Oncol Semin Origin Invest. 2005;23:402–406.
12. 12. Figiel S, Vasseur C, Bruyere F. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer. Hum Pathol. 2017;61:26-32.
13. 13. Cheng L, Nagabhushan M, Pretlow TP, et al. Expression of Ecadherin in primary and metastatic prostate cancer. Am J Pathol. 1996;148:1375–1380.
14. 14. Junior JP, Srougi M, Priscila M. A, et al. E-cadherin and B-catenin Loss of Expression Related to Bone Metastasis in Prostate Cancer. Appl Immunohistochem Mol Morphol. 2010;18:179–184.
15. 15. Rubin MA, Mucci NR, Figurski J. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol. 2001;32:690-697.
16. 16. Kuczyk M, Serth J, Machtens S, et al. Expression of E-cadherin in primary prostate cancer. Correlation with clinical features. Br J Urol. 1998;81:406-412.
17. 17. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of Ecadherin and beta catenin in human prostate cancer. Urol Oncol Semin Origin Invest. 2005;23:402–406.
18. 18. Assikis VJ, Do KA, Wen S, et al. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004;10:6770–6778.
19. 19. Horvath LG, Henshall SM, Lee CS, et al. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer. 2005;113:415–422.
20. 20. Aaltomaa S, Karja V, Lipponen P, et al. Reduced alpha and beta-catenin expression predicts shortened survival in local prostate cancer. Anticancer Res. 2005;25:4707–4712.